India mandates adverse-event reporting for GLP-1 weight-loss drugs
Monthly surveillance and enforcement tightened for drug marketing
🇮🇳
Change
India ordered mandatory monthly or bi-monthly adverse-event reporting for GLP-1 weight-loss drugs and directed stricter enforcement on improper marketing.
Why it matters
Drug manufacturers must comply with recurring pharmacovigilance reporting while regulators intensify action against surrogate advertising and off-label promotion.
Implications
- — Drugmakers must submit regular safety reports — compliance burden rises
- — Marketing violations face enforcement — regulatory risk increases
See full brief
Use 1 free preview to unlock implications, who’s affected, what to watch, and Clarify for this brief.
2 free previews left this month · Resets 1 Jul
Source